Canadian Guidelines for the Management of Plaque Psoriasis: Overview

Abstract

French

New clinical treatment guidelines for plaque psoriasis, written by a panel of 16 Canadian dermatologists, were recently published online. These Canadian Guidelines for the Management of Plaque Psoriasis are evidence based and free of any influence from corporate sponsors and have been endorsed by the Canadian Dermatology Association (CDA). The Guidelines offer treatment recommendations for mild and moderate to severe body psoriasis, as well as for psoriasis affecting specific areas of the skin, such as the facial, flexural, and genital areas; nails; scalp; and palms and soles. The present overview describes the genesis and contents of the Guidelines, which are available in full through the CDA at (English) or (French).

Get full access to this article

View all access options for this article.

References

Koo

. Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment. Dermatol Clin 1996;14:485–96, doi:10.1016/S0733-8635(05)70376-4.

Krueger

Koo

Lebwohl

. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation Patient-Membership Survey. Arch Dermatol 2001;137:280–4.

Wahl

Gjengedal

Hanestad

. The bodily suffering of living with severe psoriasis: in-depth interviews with 22 hospitalized patients with psoriasis. Qual Health Res 2002;12:250–61, doi:10.1177/104973202129119874.

Ginsburg

Link

. Feelings of stigmatization in patients with psoriasis. J Am Acad Dermatol 1989;20:53–63, doi:10.1016/S0190-9622(89)70007-4.

Vardy

Besser

Amir

. Experiences of stigmatization play a role in mediating the impact of disease severity on quality of life in psoriasis patients. Br J Dermatol 2002;147:736–42, doi:10.1046/j.1365-2133.2002.04899.x.

Schmid-Ott

Kuensebeck

Jaeger

. Validity study for the stigmatization experience in atopic dermatitis and psoriatic patients. Acta Derm Venereol 1999;79:443–7, doi:10.1080/000155599750009870.

Eghlileb

Davies

EEG

Finlay

. Psoriasis has a major secondary impact on the lives of family members and partners. Br J Dermatol 2007;156:1245–50, doi:10.1111/j.1365-2133.2007.07881.x.

Pearce

Singh

Balkrishnan

. The negative impact of psoriasis on the workplace. J Dermatolog Treat 2006;17:24–8, doi:10.1080/09546630500482886.

Heydendael

de Borgie

Spuls

. The burden of psoriasis is not determined by disease severity only. J Investig Dermatol Symp Proc 2004;9:131–5, doi:10.1111/j.1087-0024.2004.09115.x.

10.

Richards

Fortune

Weidmann

. Detection of psychological distress in patients with psoriasis: low consensus between dermatologist and patient. Br J Dermatol 2004;151:1227–33, doi: 10.1111/j.1365-2133.2004.06221.x.

11.

Jobling

. Psoriasis—a preliminary questionnaire study of sufferers' subjective experience. Clin Exp Dermatol 1976;1:233–6, doi:10.1111/j.1365-2230.1976.tb01424.x.

12.

Gelfand

Neimann

Shin

. Risk of myocardial infarction in patients with psoriasis. JAMA 2006;296:1735–41, doi:10.1001/jama.296.14.1735.

13.

Gelfand

Troxel

Lewis

. The risk of mortality in patients with psoriasis: results from a population-based study. Arch Dermatol 2007;143:1493–9, doi:10.1001/archderm.143.12.1493.

14.

Canadian Psoriasis Guidelines Committee. Canadian guidelines for the management of plaque psoriasis. June 2009. Available at: http://www.dermatology.ca/guidelines/cdnpsoriasisguidelines.pdf or http://www.dermatology.ca/guidelines/LignesdirectricespsoriasisCAN.pdf (accessed on April 2011).

15.

The AGREE Collaboration. Appraisal of Guidelines for Research & Evaluation (AGREE) Instrument. Available at: www.agreecollaboration.org (accessed November 2006).

16.

Canadian Medical Association. Handbook on clinical practice guidelines 2007. Available at: http://www.cma.ca//multimedia/CMA/Content_Images/CMAInfobase/EN/handbook.pdf (accessed June 2007).

17.

Scottish Intercollegiate Guidelines Network. SIGN 50: a guideline developers' handbook. Available at: www.sign.ac.uk (accessed November 2006).

18.

Gelfand

Weinstein

Porter

. Prevalence and treatment of psoriasis in the United Kingdom: a population-based study. Arch Dermatol 2005;141:1537–41, doi:10.1001/archderm.141.12.1537.

19.

Balkrishnan

Carroll

Camacho

Feldman

. Electronic monitoring of medication adherence in skin disease: results of a pilot study. J Am Acad Dermatol 2003;49:651–4, doi:10.1067/S0190-9622(03)00912-5.

20.

Carroll

Feldman

Camacho

Balkrishnan

. Better medication adherence results in greater improvement in severity of psoriasis. Br J Dermatol 2004;151:895–7, doi:10.1111/j.1365-2133.2004.06174.x.

21.

Ali

Brodell

Balkrishnan

Feldman

. Poor adherence to treatments: a fundamental principle of dermatology. Arch Dermatol 2007;143:912–5, doi:10.1001/archderm.143.7.912.

22.

Fouere

Adjadj

Pawin

. How patients experience psoriasis: results from a European survey. J Eur Acad Dermatol Venereol 2005;19 Suppl 3:2–6, doi:10.1111/j.1468-3083.2005.01329.x.

23.

Richards

Fortune

O'Sullivan

. Patients with psoriasis and their compliance with medication. J Am Acad Dermatol 1999;41:581–3.

24.

Mason

Cork

. Topical preparations for the treatment of psoriasis: a systematic review. Br J Dermatol 2002;146: 351–64, doi:10.1046/j.1365-2133.2000.04713.x.

25.

Ashcroft

Li Wan Po

Williams

Griffiths

CEM

. Systematic review of comparative efficacy and tolerability of calcipotriol in treating chronic plaque psoriasis. BMJ 2000;320: 963–7, doi:10.1136/bmj.320.7240.963.

26.

Papp

Guenther

Boyden

. Early onset of action and efficacy of a combination of calcipotriene and betamethasone dipropionate in the treatment of psoriasis. J Am Acad Dermatol 2003;48:48–54, doi:10.1067/mjd.2003.130.

27.

Al-Suwaidan

Feldman

. Clearance is not a realistic expectation of psoriasis treatment. J Am Acad Dermatol 2000;42: 796–802, doi:10.1067/mjd.2000.103983.

28.

Lynde

Poulin

Guenther

Jackson

. The burden of psoriasis in Canada: insights from the pSoriasis Knowledge IN Canada (SKIN) survey. J Cutan Med Surg 2009;13:235–52.

29.

Mahler

Jackson

Ijacu

. The burden of psoriasis and barriers to satisfactory care: results from a Canadian patient survey. J Cutan Med Surg 2009;13:283–93.

30.

Wasel

Poulin

Andrew

. A Canadian self-administered online survey to evaluate the impact of moderate-to-severe psoriasis among patients. J Cutan Med Surg 2009;13:294–302.

31.

Papp

Carey

. Psoriasis care: new and emerging pharmacologic trends. J Cutan Med Surg 2010;14:119–29.

32.

Statistics Canada. Age (123) and sex (3) for the population of Canada, 2006 census. Available at: http://www12.statcan.ca/english/census06/data/topics/RetrieveProductTable.cfm?Temporal=2006&APATH=3&PID=88989&THEME=66&PTYPE=88971&VID=0&GK=NA&GC=99&FL=0&RL=0&FREE=0&METH=0&S=1 (accessed January 2008).

33.

Anstey

Kragballe

. Retrospective assessment of PASI 50 and PASI 75 attainment with a calcipotriol/betamethasone dipropionate ointment. Int J Dermatol 2006;45:970–5, doi:10.1111/j.1365-4632.2006.02939.x.

34.

Van De Kerkhof

PCM

. Update on retinoid therapy of psoriasis in: an update on the use of retinoids in dermatology. Dermatolog Ther 2006;19:252–63, doi:10.1111/j.1529-8019.2006.00082.x.

35.

Olsen

Weed

Meyer

Cobo

. A double-blind, placebo-controlled trial of acitretin for the treatment of psoriasis. J Am Acad Dermatol 1989;21:681–6, doi:10.1016/S0190-9622(89)70236-X.

36.

Griffiths

Albrecht

. Intermittent short courses of cyclosporin (Neoral(R)) for psoriasis unresponsive to topical therapy: a 1-year multicentre, randomized study. The PISCES Study Group. Br J Dermatol 1999;141:283–91, doi:10.1046/j.1365-2133.1999.02977.x.

37.

VCY

Griffiths

CEM

Berth-Jones

. Intermittent short courses of cyclosporine microemulsion for the long-term management of psoriasis: a 2-year cohort study. J Am Acad Dermatol 2001;44:643–51, doi:10.1067/mjd.2001.112400.

38.

Grossman

Chevret

Abi-Rached

. Long-term safety of cyclosporine in the treatment of psoriasis. Arch Dermatol 1996; 132:623–9, doi:10.1001/archderm.132.6.623.

39.

Faerber

Braeutigam

Weidinger

. Cyclosporine in severe psoriasis: results of a meta-analysis in 579 patients. Am J Clin Dermatol 2001;2:41–7, doi: 10.2165/00128071-200102010-00007.

40.

Zachariae

Kragballe

Sogaard

. Methotrexate induced liver cirrhosis. Studies including serial liver biopsies during continued treatment. Br J Dermatol 1980;102:407–12, doi:10.1111/j.1365-2133.1980.tb06553.x.

41.

Malatjalian

Ross

Williams

. Methotrexate hepatotoxicity in psoriatics: report of 104 patients from Nova Scotia, with analysis of risks from obesity, diabetes and alcohol consumption during long term follow-up. Can J Gastroenterol 1996;10:369–75.

42.

Salim

Tan

Ilchyshyn

Berth-Jones

. Folic acid supplementation during treatment of psoriasis with methotrexate: a randomized, double-blind, placebo-controlled trial. Br J Dermatol 2006;154:1169–74, doi: 10.1111/j.1365-2133.2006.07289.x.

43.

Heydendael

VMR

Spuls

Opmeer

. Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis. N Engl J Med 2003;349:658–65, doi:10.1056/NEJMoa021359.

44.

Van Dooren-Greebe

Kuijpers

ALA

Mulder

. Methotrexate revisited: effects of long-term treatment in psoriasis. Br J Dermatol 1994;130:204–10, doi:10.1111/j.1365-2133.1994.tb02901.x.

45.

Schiff

Burmester

Kent

. Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann Rheum Dis 2006;65:889–94, doi:10.1136/ard.2005.043166.

46.

Menter

Tyring

Gordon

. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol 2008;58:106–15, doi:10.1016/j.jaad.2007.09.010.

47.

Saurat

Stingl

Dubertret

. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol 2008;158:558–66.

48.

Mohan

Edwards

Cupps

. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum 2001;44:2862–9, doi:10.1002/1529-0131(200112)44:12<2862::AID-ART474>3.0.C0;2-W.

49.

Fulchiero

Jr Salvaggio

Drabick

. Eruptive latent metastatic melanomas after initiation of antitumor necrosis factor therapies. J Am Acad Dermatol 2007;56(5 Suppl):S65–7, doi:10.1016/j.jaad.2006.12.024.

50.

Gordon

Korman

Frankel

. Efficacy of etanercept in an integrated multistudy database of patients with psoriasis. J Am Acad Dermatol 2006;54(3 Suppl 2):S101–11, doi:10.1016/j.jaad.2005.11.1088.

51.

Leonardi

Powers

Matheson

. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003;349: 2014–22, doi:10.1056/NEJMoa030409.

52.

Papp

Tyring

Lahfa

. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol 2005;152:1304–12, doi:10.1111/j.1365-2133.2005.06688.x.

53.

Menter

Feldman

Weinstein

. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol 2007;56(1):31.el–15, doi:10.1016/j.jaad.2006.07.017.

54.

Smith

Jackson

Bashir

. Infliximab for severe, treatment-resistant psoriasis: a prospective, open-label study Br J Dermatol 2006;155:160–9, doi: 10.1111/j.1365-2133.2006.07316.x.

55.

Reich

Nestle

Papp

. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 2005;366:1367–74, doi:10.1016/S0140-6736(05)67566-6.

56.

Krathen

Berthelot

Hsu

. Sustained efficacy and safety of infliximab in psoriasis: a retrospective study of73 patients. J Drugs Dermatol 2006;5:251–4.

57.

Goffe

Papp

Gratton

. An integrated analysis of thirteen trials summarizing the long-term safety of alefacept in psoriasis patients who have received up to nine courses of therapy. Clin Ther 2005;27:1912–21, doi:10.1016/j.clinthera.2005.12.007.

58.

Legat

Hofer

Wackernagel

. Narrowband UV-B phototherapy, alefacept, and clearance of psoriasis. Arch Dermatol 2007;143:1016–22, doi:10.1001/archderm.143.8.1016.

59.

Gordon

Langley

. Remittive effects of intramuscular alefacept in psoriasis. J Drugs Dermatol 2003;2:624–8.

60.

Lebwohl

Christophers

Langley

. An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch Dermatol 2003;139:719–27, doi:10.1001/archderm.139.6.719.

61.

Nijsten

TEC

Stern

. The increased risk of skin cancer is persistent after discontinuation of psoralen + ultraviolet A: a cohort study. J Invest Dermatol 2003;121:252–8, doi:10.1046/j.1523-1747.2003.12350.x.

62.

Tzaneva

Honigsmann

Tanew

Seeber

. A comparison of psoralen plus ultraviolet A (PUVA) monotherapy, tacalcitol plus PUVA and tazarotene plus PUVA in patients with chronic plaque-type psoriasis. Br J Dermatol 2002;147:748–53, doi:10.1046/j.1365-2133.2002.04896.x.

63.

Iest

Boer

. Combined treatment of psoriasis with acitretin and UVB phototherapy compared with acitretin alone and UVB alone. Br J Dermatol 1989;120:665–70, doi:10.1111/j.1365-2133.1989.tb01354.x.

64.

Tanew

Guggenbichler

Honigsmann

. Photochemotherapy for severe psoriasis without or in combination with acitretin: a randomized, double-blind comparison study. J Am Acad Dermatol 1991;25:682–4, doi:10.1016/0190-9622(91)70253-X.

65.

Schiener

Brockow

Franke

. Bath PUVA and saltwater baths followed by UV-B phototherapy as treatments for psoriasis: a randomized controlled trial. Arch Dermatol 2007;143:586–96, doi:10.1001/archderm.143.5.586.

66.

Yones

Palmer

Garibaldinos

Hawk

JLM

. Randomized double-blind trial of the treatment of chronic plaque psoriasis: efficacy of psoralen-UV-A therapy vs narrowband UV-B therapy. Arch Dermatol 2006;142:836–42, doi:10.1001/archderm.142.7.836.

67.

Markham

Rogers

Collins

. Narrowband UV-B (TL-01) phototherapy vs oral 8-methoxypsoralen psoralen - UV-A for the treatment of chronic plaque psoriasis. Arch Dermatol 2003;139: 325–8, doi:10.1001/archderm.139.3.325.

68.

Gordon

Diffey

Matthews

Farr

. A randomized comparison of narrow-band TL-01 phototherapy and PUVA photochemotherapy for psoriasis. J Am Acad Dermatol 1999;41: 728–32, doi:10.1016/S0190-9622(99)70008-3.